Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2021
Relmada prices upsized public stock offering
Relmada Therapeutics announced pricing of an upsized underwritten public offering of 8,823,530 common shares at $17 per share, with gross proceeds expected to be approximately $150 million. The offering was expected to close on December 13, 2021, subject to customary conditions.
2020
Relmada appoints Molly Harper as EVP of Operations
Relmada Therapeutics announced Molly Harper's appointment as Executive Vice President of Operations, with oversight of operations across company functions.